Get to know our clinical trials
Phase 1/1b, open-label, multicenter, stepwise escalation and dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of KQB198 in monotherapy and in combination with antineoplastics in participants with advanced solid malignancies
THE AIM IS TO TEST AN INVESTIGATIONAL (EXPERIMENTAL) DRUG CALLED KQB198 THAT COULD HELP STOP THE GROWTH OF CANCER CELLS.
Specialist
Medical Oncology Department
Navarre headquarters
Technical Summary
- PHASE 1/1B, OPEN-LABEL, MULTICENTER, STEPWISE ESCALATION AND DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF KQB198 IN MONOTHERAPY AND IN COMBINATION WITH ANTINEOPLASTICS IN PARTICIPANTS WITH ADVANCED SOLID MALIGNANCIES
- Code EudraCT: 2024-511457-22
- Protocol number: KQB198-101
- Promoter: Kumquat Biosciences, Inc.
- Molecule/Drug: KQB198
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.